Two studies of a new pill for multiple sclerosis (MS) suggest it may reduce relapses and disability progression in people with the more common, relapsing-remitting form of the neurological condition, which accounts for around 85% of cases. The studies report the results of two phase 3 clinical...
A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease. The results of the Phase 3 trial of the drug teriflunomide were published in The New England Journal of...
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly...
The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS). "Gilenya is the first oral drug that can slow the progression of disability and reduce the...